Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib maintenance dose-comparison study in adults with FLT3-ITD positive AML in first complete remission
CTR20252304Phase 2Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd.. Started Oct 2025; status: active.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20252304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252304.